IMU is building a clinical-scale immune profiling platform that combines high-fidelity multi-omic analysis with proprietary machine learning to measure over 100 million immune data points from a simple 2ml blood sample. By resolving 2,500 discrete immune cell subsets in real time, IMU is creating the most detailed picture of the immune system ever assembled at clinical scale, with the world's largest immune dataset underpinning a new generation of precision medicine.

IMU originates from research carried out at the Francis Crick Institute and King's College London, and is founded by a team of leading experimental immunologists and computational biologists. The company is advancing clinical programmes across stem cell and organ transplantation, and immuno-oncology.